» Articles » PMID: 33962555

Mechanism and Risk Factors of Nausea and Vomiting After TACE: a Retrospective Analysis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2021 May 8
PMID 33962555
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The mechanism of postoperative nausea and vomiting after TACE is not clear. This study retrospectively analyzed the patient data to explore the mechanism and risk factors of postoperative nausea and vomiting after TACE.

Materials And Methods: The data of 221 patients who underwent TACE in the interventional department from January 2019 to December 2020 were collected. Including: gender, age, liver function before TACE, etiology of liver cirrhosis, BCLC stage of hepatocellular carcinoma, preoperative use of analgesic drugs, preoperative limosis, previous history of vomiting, history of kinetosis, smoking history, history of drinking, chemotherapeutic drugs used during TACE, Dosage of lipiodol, and occurrence of postoperative nausea and vomiting.

Results: There were 116 cases of nausea after TACE, using binary logistic regression analysis, Sig: ALT0.003; ALP0.000; history of vomiting 0.043; kinetosis 0.006; history of alcohol consumption 0.011; preoperative limosis 0.006; dosage of lipiodol (5-10 mL) 0.029, dosage of lipiodol (> 10 mL) 0.001.There were 89 cases of vomiting after TACE, all accompanied by nausea, Sig: ALP0.000; BCLC stage (B) 0.007; kinetosis 0.034; chemotherapeutic drugs 0.015; dosage of lipiodol (5-10 ml) 0.015, dosage of lipiodol (> 10 ml) 0.000; patients used analgesics before TACE 0.034.

Conclusions: Causes of post-TACE nausea and vomiting included operative trauma, aseptic inflammation caused by ischemia and hypoxia, chemotherapeutic drugs, ischemia of liver and bile duct, stress and pain during TACE, and patient factors. ALP, BCLC stage, kinetosis, chemotherapeutic drugs, dosage of lipiodol, and preoperative usage of analgesics were risk factors affecting nausea and vomiting after TACE.

Citing Articles

Risk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study.

Wang Y, Zhou X, Li G, Lv Q, Li X, Yan Z Curr Oncol. 2025; 32(1).

PMID: 39851933 PMC: 11764149. DOI: 10.3390/curroncol32010017.


The Efficacy and Adverse Effects of Sugammadex and Neostigmine in Reversing Neuromuscular Blockade Inpatients with Obesity Undergoing Metabolic and Bariatric Surgery: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.

Wang S, Dong Y, Wang S, Han Y, Li Q Medicina (Kaunas). 2024; 60(11).

PMID: 39597027 PMC: 11596585. DOI: 10.3390/medicina60111842.


Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients.

Sun Y, Zhang H, Li Y, Zhou C, Han J Front Immunol. 2024; 15:1450525.

PMID: 39439786 PMC: 11493604. DOI: 10.3389/fimmu.2024.1450525.


Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization.

Wang X, Wang J, Li J, Liang K, Dai S, Wang R BMC Gastroenterol. 2024; 24(1):333.

PMID: 39350028 PMC: 11441167. DOI: 10.1186/s12876-024-03427-0.


Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma.

Lu H, Liang B, Xia X, Zheng C BMC Cancer. 2024; 24(1):1085.

PMID: 39223485 PMC: 11367810. DOI: 10.1186/s12885-024-12864-9.


References
1.
Han K, Kim J . Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015; 21(36):10327-35. PMC: 4579879. DOI: 10.3748/wjg.v21.i36.10327. View

2.
Berger M, Ettinger D, Aston J, Barbour S, Bergsbaken J, Bierman P . NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(7):883-893. DOI: 10.6004/jnccn.2017.0117. View

3.
Horn C, Wallisch W, Homanics G, Williams J . Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol. 2014; 722:55-66. PMC: 3915298. DOI: 10.1016/j.ejphar.2013.10.037. View

4.
Cao X, White P, Ma H . An update on the management of postoperative nausea and vomiting. J Anesth. 2017; 31(4):617-626. DOI: 10.1007/s00540-017-2363-x. View

5.
Wiesmann T, Kranke P, Eberhart L . Postoperative nausea and vomiting - a narrative review of pathophysiology, pharmacotherapy and clinical management strategies. Expert Opin Pharmacother. 2015; 16(7):1069-77. DOI: 10.1517/14656566.2015.1033398. View